AbCellera completed the acquisition of Trianni for $90m.

AbCellera, a technology company that searches, decodes, and analyzes natural immune systems, completed the acquisition of Trianni, a company that specializes in antibody discovery technology using transgenic mice, for $90m. “Trianni marks our fourth and largest strategic technology addition to date. With its technology and team, Trianni amplifies our capability to generate human antibodies and provides a strong foundation for developing increasingly powerful transgenic mouse technologies. Trianni adds a key pillar to our platform, which now includes genetically engineered rodents, microfluidic single-cell screening, repertoire sequencing, AI-powered computation, and bispecific protein engineering. By integrating these technologies, we aim to provide our partners with access to a modern operating system that improves the speed and probability of success of antibody drug development," Carl Hansen, AbCellera CEO.